August 4^th, 2022: Myelo Therapeutics to Receive Multi-Million Euro Grant from the European Defense Fund for Development of Medical Countermeasures

July 28^th, 2022: Myelo Therapeutics Receives Additional NIAID Funding For Development Myelo001 in Acute Radiation Syndrome

February 13^th, 2022: Myelo Therapeutics Receives Scientific Advice by EMA for the development of Myelo001 for Acute Radiation Syndrome

June 4^th, 2021: Myelo Therapeutics Receives Additional NIAID funding to Advance Development of Myelo001 in Acute Radiation Syndrome

March 3^rd, 2021: Myelo Therapeutics Expands NIH-NIAID Collaboration and Joins Bayer Pharmaceuticals Incubator

June 26^th, 2020: Myelo Therapeutics Closes Financing Round and Gains Strong Backing of Eckert & Ziegler Group.

May 11^th, 2020: Myelo Therapeutics Awarded NIH-NIAID Contract Valued up to $6 Million for Development of Myelo001 as Treatment for Acute Radiation Syndrome.

Nov 4^th, 2019: New data confirming Myelo001 efficacy in Acute Radiation Syndrome presented at 65th annual meeting of the Radiation Research Society.

July 24^th, 2019: EMA Grants Myelo Therapeutics Orphan Drug Designation for Myelo001 as Treatment for Acute Radiation Syndrome.

Dec 4^th, 2018: Positive Data on Efficacy of Myelo001 in treating Acute Radiation Syndrome published in Blood.

Sep 25^th, 2018: FDA Grants Myelo Therapeutics Orphan Drug Designation for Myelo001 as Treatment for Acute Radiation Syndrome.

March 1^st, 2018: Myelo Therapeutics has been selected as a finalist of the Lyfebulb-Helsinn Innovation Summit Award in Oncology..

Nov 8^th, 2017: Interview on progress of Myelo001 development program and Myelo Therapeutics experience with Elsevier’s “The Hive” incubator program.

Oct 4^th, 2017: Myelo Therapeutics’ Phase II study of Myelo001 in Chemotherapy-induced Neutropenia is fully recruited.

June 20^th, 2017: Myelo Therapeutics conducts successful Pre-IND meeting with U.S. Food and Drug Administration (FDA) for Myelo001 and completes new financing round.

Jan 16^th, 2017: New data published in Blood confirms that the chemo-protective effect of Myelo001 is specific to healthy tissue.